Introduction
Epilepsy is one of the most frequent neurological disorders with a high prevalence in most populations. It is therefore not unusual to observe families in which more than one member is affected. However, most of these ''familial'' cases are multifactorial in origin and only a minority of them are caused by single gene mutations. Several examples of such rare genetic epilepsies for which causative genes were identified have been published during the last two decades, the most recent one being infantile convulsions with choreoathetosis syndrome (ICCA, OMIM 602066). [1] [2] [3] [4] [5] [6] Typically patients with this rare syndrome are temporarily afflicted with benign seizures that mostly occur between age 6 months and two years. The seizures are tonic, tonic-clonic or atonic and can be accompanied by gazing, unresponsiveness, cyanosis or head deviation. During childhood or young adulthood the patients develop paroxysmal dyskinesia that is characterized by short attacks of dystonic posturing and choreatiform or athetotic movements lasting for up to 5 min.
Monogenic forms of infantile seizures without choreoathetosis exist, known as separate genetic entities named benign familial infantile convulsions (BFIC; OMIM 605751) or Fukuyama-Watanabe-Vigevano syndrome. 7 Both ICCA and BFIC have been previously linked to the same region on chromosome 16. 8, 9 Recently, several groups described mutations in PRRT2 (prolinerich transmembrane protein 2), a gene located in the chromosome 16 candidate region. 1, 10 The PRRT2 mutations were mainly found in patients with either typical ICCA or isolated paroxysmal kinesigenic dyskinesia without preceding epilepsy. Furthermore, some PRRT2 mutations were described in patients with infantile convulsions without choreoathetosis, suggesting that ICCA and BFIC are allelic. 6 This hypothesis is supported by the families presented here.
Methods
Blood samples were taken from the index patients and their relatives from five BFIC families. All families were of German descent. The patients provided informed consent for molecular testing and the study was approved by the local ethics committee. The families (with the exception of family D124 which was recruited in 2012) were collected between 1995 and 2002, at which point information about seizure onset and seizure type as well as about psychomotor development were collected. They were clinically re-evaluated in 2012, and information was gathered about seizure remission, neurological status and movement disorders. These data were obtained from the clinicians that treated the patients during recruitment and who saw them again for clinical evaluation in 2012. The complete coding sequence of the PRRT2 gene was amplified by PCR and directly sequenced using the Sanger method.
Results
The clinical details of the five BFIC families included in this study are summarized in supplementary Table 1 . The index patients of these families (except D124) had been previously tested negative for mutation in the KCNQ2 and KCNQ3 genes by direct sequencing of the coding regions. The previously described truncating PRRT2 mutation c.649dupC was found in all BFIC patients for whom DNA was available but not in their unrelated spouses. Within the five BFIC families five unaffected carriers (either obligate (D12-II3, D75-II3) or proven to carry the mutation (D75-III2, D96-IV1+3) were identified, indicating a reduced penetrance for PRRT2-c.649dupC in our sample. The affected carriers of this mutation presented with a wide spectrum of epileptic seizures during their first two years of life. These included complex focal seizures, secondary generalized tonic clonic seizures, as well as absence seizures. Clinical re-evaluation of all families (except the recently recruited Family D124) 10-17 years after the initial evaluation showed that none of the index patients or affected family members developed choreoathetosis or other neurological symptoms (except for migraine in D96-IV4 and in her unaffected cousin (D96-IV1) who is a carrier of mutation c.649dupC). In all patients seizures remitted either spontaneously or after antiepileptic drug treatment was initiated, and no recurrence occurred after treatment was discontinued. Psychomotor development was normal in all patients.
Discussion
The human PRRT2 transcripts are primarily found in brain, especially in basal ganglia and cortex (Ensembl). In mice they are predominantly expressed in brain and spinal cord during embryonic development and the postnatal stage. 3 Three different PRRT2 isoforms are encoded by transcripts that are alternatively spliced in their 3 0 ends. The known mutations (Table 1) are located in the part of the PRRT2 protein that all splice variants have in common, thus the isoforms are unlikely to affect the clinical outcome. The physiological functions of the different PRRT2 isoforms are largely unknown. Structural analysis predicts the existence of transmembrane domains, thus PRRT2 is likely to be membrane bound. Yeast two-hybrid studies suggested an nteraction with SNAP25 (synaptosomal-associated protein 25 kDa), a protein known to be involved in neurotransmitter release from synaptic vesicles. Thus it is possible that PRRT2 is indirectly involved in synaptic transmission, a physiological process crucial for most brain functions. An association between a membrane spanning protein and a clinical phenotype that combines both epilepsy and movement disorder has been previously described in the glucose transporter-1 deficiency syndrome, caused by mutations in the SLC2A1 gene.
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Heterozygous truncating mutations such as PRRT2 c.649dupC are likely to significantly decrease the amount of available protein. They can even cause a dominant negative effect in which the truncated protein interferes with the normal PRRT2 protein transcribed from second allele. Both mechanisms can be predicted to result in a considerable loss-of-function effect. The mutation c.649dupC is the most commonly found alteration in both paroxysmal kinesigenic dyskinesia and ICCA patients (108/ 120 published patients, see Table 1 ). The data reported here confirm that this specific PRRT2 mutation is also so far the most frequent cause of BIFC. It is not known why one and the same mutation can cause both epilepsy and movement disorder in some patients, but only epilepsy in others. In most of the previous publications both clinical phenotypes coexisted in families with this mutation. 1, 10 Our five families show that c.649dupC can be associated with a uniform intrafamilial clinical outcome. The 21 patients reported here (18 of them proven mutation carriers, 3 clinically affected but not genetically tested; Fig. 1 ) all had a benign type of early childhood epilepsy but none of them developed paroxysmal kinesigenic dyskinesia or related neurological symptoms. One possible explanation for this uniform clinical expression would be ascertainment bias, meaning that we were collecting familial epilepsies and patients with the more severe phenotype of paroxysmal kinesigenic dyskinesia might simply have not been reported to us. This explanation is less likely because most of our index patients were recruited by neuropaediatricians that encountered these patients years before the movement disorder in ICCA usually starts. Another explanation would be that the mutation c.649dupC by itself is not sufficient to cause the later onset neurological phenotype of paroxysmal kinesigenic dyskinesia but that so far unknown additional genetic or environmental factors are necessary for such an outcome. The latter hypothesis is supported by the fact that the previously reported families with PRRT2-c.649dupC originated from China, Japan and Australia while our families were of German descent. Such differences in origin are likely to be associated with differences in both genetic background and environment. It will be interesting to identify additional c.649dupC patients from adjacent European countries to find out if they share the uniformly benign clinical outcome observed in our German family sample, or if the epilepsy-only phenotype described here is an artefact caused by the small sample size.
